Science News
from research organizations

The Path To New Antibiotics

Date:
August 28, 2009
Source:
Burnham Institute
Summary:
Researchers have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens. In addition, investigators discovered chemical compounds that can inhibit this enzyme and suppress the growth of pathogenic bacteria. These findings are essential to develop new broad-spectrum antibacterial agents to overcome multidrug resistance.
Share:
         
Total shares:  
FULL STORY

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens. In addition, investigators discovered chemical compounds that can inhibit this enzyme and suppress the growth of pathogenic bacteria. These findings are essential to develop new broad-spectrum antibacterial agents to overcome multidrug resistance.

The research was published in the Cell journal Chemistry & Biology on August 27.

Andrei Osterman, Ph.D., an associate professor in Burnham’s Bioinformatics and Systems Biology program, and colleagues, targeted the bacterial nicotinate mononucleotide adenylyltransferase (NadD), an essential enzyme for nicotinamide adenine dinculeotide (NAD) biosynthesis. NAD has many crucial functions in nearly all important pathogens and the bacterial NadD differs significantly from the human enzyme.

“It’s clear that because of bacterial resistance, we need new, wide-spectrum antibiotics,” said Dr. Osterman. “This enzyme is indispensable in many pathogens, so finding ways to inhibit it could give us new options against infection.”

According to the National Institutes of Health, drug resistance is making many diseases increasingly difficult—and sometimes impossible—to treat. They point to tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA) as two pathogens that pose a serious threat to human health.

Using a structure-based approach, the team searched for low-molecular-weight compounds that would selectively inhibit bacterial NadD, but not the human equivalent, by screening, in silico, more than a million compounds. Experimental testing of the best predicted compounds against Escherichia coli and Bacillus anthracis (anthrax) led them to a handful of versatile inhibitory chemotypes, which they explored in detail. Using protein crystallography, a 3D structure of the enzyme in complex with one of the inhibitors was solved providing guidelines for further drug improvement.

“This is proof-of-concept that NadD is a good target to create antibacterial agents,” said Dr Osterman. “This knowledge will be useful for both biodefense and public health. The next step is to find better inhibitors. We do not have a silver bullet yet, but we are certainly hitting a golden target.”

This research was supported by a grant from the National Institute of Allergy and Infectious Diseases.


Story Source:

The above story is based on materials provided by Burnham Institute. Note: Materials may be edited for content and length.


Cite This Page:

Burnham Institute. "The Path To New Antibiotics." ScienceDaily. ScienceDaily, 28 August 2009. <www.sciencedaily.com/releases/2009/08/090827131830.htm>.
Burnham Institute. (2009, August 28). The Path To New Antibiotics. ScienceDaily. Retrieved May 7, 2015 from www.sciencedaily.com/releases/2009/08/090827131830.htm
Burnham Institute. "The Path To New Antibiotics." ScienceDaily. www.sciencedaily.com/releases/2009/08/090827131830.htm (accessed May 7, 2015).

Share This Page:


Recommended Content
 


Plants & Animals News
May 7, 2015

Latest Headlines
updated 12:56 pm ET